PineBridge Investments’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $6.28M | Sell |
10,068
-3,239
| -24% | -$2.2M | 0.05% | 235 |
|
|
2026
Q1 | $10.3M | Buy |
13,307
+1,852
| +16% | +$1.42M | 0.09% | 172 |
|
|
2025
Q4 | $8.84M | Buy |
11,455
+565
| +5% | +$384K | 0.07% | 185 |
|
|
2025
Q3 | $6.12M | Buy |
10,890
+6,248
| +135% | +$3.53M | 0.05% | 250 |
|
|
2025
Q2 | $2.44M | Buy |
4,642
+1,079
| +30% | +$602K | 0.02% | 402 |
|
|
2025
Q1 | $2.26M | Sell |
3,563
-407
| -10% | -$280K | 0.02% | 408 |
|
|
2024
Q4 | $2.83M | Sell |
3,970
-22,735
| -85% | -$19.1M | 0.02% | 452 |
|
|
2024
Q3 | $28.1M | Sell |
26,705
-2,550
| -9% | -$2.84M | 0.21% | 109 |
|
|
2024
Q2 | $30.7M | Sell |
29,255
-9,127
| -24% | -$8.85M | 0.25% | 94 |
|
|
2024
Q1 | $36.9M | Buy |
38,382
+2,753
| +8% | +$2.62M | 0.29% | 70 |
|
|
2023
Q4 | $31.3M | Sell |
35,629
-627
| -2% | -$516K | 0.29% | 76 |
|
|
2023
Q3 | $29.8M | Buy |
36,256
+5,640
| +18% | +$4.43M | 0.33% | 78 |
|
|
2023
Q2 | $22M | Sell |
30,616
-20,956
| -41% | -$16.2M | 0.24% | 103 |
|
|
2023
Q1 | $42.4M | Sell |
51,572
-599
| -1% | -$452K | 0.48% | 49 |
|
|
2022
Q4 | $37.6M | Sell |
52,171
-13,205
| -20% | -$9.74M | 0.46% | 51 |
|
|
2022
Q3 | $45M | Sell |
65,376
-3,498
| -5% | -$2.2M | 0.58% | 33 |
|
|
2022
Q2 | $40.7M | Buy |
68,874
+47,635
| +224% | +$31M | 0.51% | 42 |
|
|
2022
Q1 | $14.8M | Buy |
21,239
+3,515
| +20% | +$2.22M | 0.16% | 154 |
|
|
2021
Q4 | $11.2M | Buy |
+17,724
| New | +$10.9M | 0.11% | 189 |
|
|
2021
Q2 | – | Sell |
-119
| Closed | -$56K | – | 680 |
|
|
2021
Q1 | $56K | Sell |
119
-3,255
| -96% | -$1.58M | ﹤0.01% | 604 |
|
|
2020
Q4 | $1.63M | Sell |
3,374
-15
| -0.4% | -$8.1K | 0.03% | 443 |
|
|
2020
Q3 | $1.9M | Sell |
3,389
-4,528
| -57% | -$2.75M | 0.03% | 393 |
|
|
2020
Q2 | $4.94M | Buy |
7,917
+5,728
| +262% | +$3.25M | 0.09% | 226 |
|
|
2020
Q1 | $1.07M | Buy |
2,189
+1,975
| +923% | +$815K | 0.03% | 374 |
|
|
2019
Q4 | $80K | Sell |
214
-4,259
| -95% | -$1.43M | ﹤0.01% | 901 |
|
|
2019
Q3 | $1.24M | Sell |
4,473
-4,530
| -50% | -$1.34M | 0.02% | 650 |
|
|
2019
Q2 | $2.82M | Buy |
+9,003
| New | +$3M | 0.05% | 300 |
|
|
2019
Q1 | – | Sell |
-7,057
| Closed | -$2.64M | – | 1137 |
|
|
2018
Q4 | $2.64M | Buy |
7,057
+3,776
| +115% | +$1.38M | 0.06% | 268 |
|
|
2018
Q3 | $1.32M | Buy |
+3,281
| New | +$1.25M | 0.03% | 516 |
|
|
2018
Q1 | – | Sell |
-39
| Closed | -$15K | – | 1160 |
|
|
2017
Q4 | $15K | Buy |
39
+5
| +15% | +$2.02K | ﹤0.01% | 1006 |
|
|
2017
Q3 | $15K | Buy |
34
+9
| +36% | +$4.28K | ﹤0.01% | 1136 |
|
|
2017
Q2 | $12K | Sell |
25
-255
| -91% | -$112K | ﹤0.01% | 1110 |
|
|
2017
Q1 | $108K | Sell |
280
-331
| -54% | -$123K | ﹤0.01% | 914 |
|
|
2016
Q4 | $224K | Buy |
611
+176
| +40% | +$66.9K | 0.01% | 816 |
|
|
2016
Q3 | $174K | Sell |
435
-71
| -14% | -$28.5K | 0.01% | 557 |
|
|
2016
Q2 | $177K | Sell |
506
-287
| -36% | -$111K | 0.01% | 539 |
|
|
2016
Q1 | $286K | Sell |
793
-752
| -49% | -$310K | 0.01% | 370 |
|
|
2015
Q4 | $839K | Sell |
1,545
-1,680
| -52% | -$910K | 0.04% | 253 |
|
|
2015
Q3 | $1.5M | Buy |
+3,225
| New | +$1.73M | 0.06% | 201 |
|
Other funds holding REGN
PineBridge Investments's REGN Position: Q2 2026 in Review
PineBridge Investments reduced its Regeneron Pharmaceuticals (REGN) stake by 24% in Q2 2026, selling an estimated $2.2M and leaving 10,068 shares worth $6.28M. The position accounts for 0.05% of the portfolio, ranked #235.
PineBridge Investments first reported a position in REGN in Q3 2015 and has held it in 39 quarters since. The position peaked at $45M in Q3 2022. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- PineBridge Investments held 10,068 shares of Regeneron Pharmaceuticals worth $6.28M as of Q2 2026.
- PineBridge Investments sold 3,239 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $2.2M.
- Regeneron Pharmaceuticals made up 0.05% of PineBridge Investments's portfolio in Q2 2026, its #235 holding.
- PineBridge Investments first reported a position in Regeneron Pharmaceuticals in Q3 2015 and has held it in 39 quarters since.
- PineBridge Investments's Regeneron Pharmaceuticals position peaked at $45M in Q3 2022.
- 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on PineBridge Investments's 13F filing for Q2 2026, filed 14 Aug 2026.